Verastem Oncology’s lead development program focuses on dual inhibition of phosphoinositide 3-kinase (PI3K-delta and PI3K-gamma).

Analyst & Investor Day 2018

In May 2018, Verastem Oncology hosted an Analyst & Investor Day – “Duvelisib: Harnessing the Power of Dual PI3K Inhibition.” Leading experts in hematologic malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), and peripheral T-cell lymphoma (PTCL), provided an in-depth discussion regarding the current U.S. treatment landscape, where phosphoinositide-3-kinase (PI3K)- inhibitors fit into the treatment paradigm and the need for new anti-cancer agents, including duvelisib. Below are highlights from the program.

Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, Physician, Founder & President of the CLL Society, and CLL patient discussed the CLL patient journey, along with the learnings and challenges of living with high-risk disease.

Jennifer Brown, MD, PhD, Director of the CLL Center of the Division of Hematologic Malignancies, Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School, gave a compelling presentation on the role of PI3K inhibitors as treatment evolves towards a chemo-free future for many patients with B-cell malignancies.

Ian Flinn, MD, PhD, Director, Blood Cancer Research Program at Sarah Cannon Research Institute presented data from the DUO™ and DYNAMO™ studies, the basis for the New Drug Application for duvelisib.

Dr. Steve Horwitz, Medical Oncologist at Memorial Sloan Kettering, presented an overview of the unmet need for new strategies in T-cell lymphoma.